We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01647568
First Posted: July 23, 2012
Last Update Posted: July 23, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Linda A Feagins, Dallas VA Medical Center
  Purpose

At our VA hospital, in general, it is the policy of our GI lab to not stop our patients anti-platelet therapy whenever they see us for a routine colonoscopy. We do this because we believe the risk of stopping these sort of medications outweigh the risks of a complication from a colonoscopy.

Therefore, we are enrolling patients who are either on clopidogrel or prasugrel or not on any anti-platelet/anti-coagulant therapy that come to our GI lab routine colonoscopies. We perform the procedure just like we normally would and then follow-up with the patient 7 and 30 days after their procedure.


Condition
Post-polypectomy Bleeding Anti-platelet Therapy Colonoscopy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Linda A Feagins, Dallas VA Medical Center:

Enrollment: 715
Study Start Date: December 2009
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Control
Patients who are not on any anti-platelet/anti-coagulant therapy and present to our lab for a elective colonoscopy.
Thienopyridine Users
Patients on Clopidogrel or prasugrel when they present for an elective colonoscopy.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients presenting to the GI lab for elective colonoscopy.
Criteria

Inclusion Criteria:

  • Patients presenting to the GI lab for elective colonoscopy

Exclusion Criteria:

  • Patients on Coumadin or other anti-coagulants
  • Patients with Inflammatory Bowel Disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01647568


Locations
United States, Texas
Dallas VA Medical Center
Dallas, Texas, United States, 75216
Sponsors and Collaborators
Dallas VA Medical Center
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Linda A Feagins, Staff Gastroenterologist, Dallas VA Medical Center
ClinicalTrials.gov Identifier: NCT01647568     History of Changes
Other Study ID Numbers: DVAMC-09-084
First Submitted: July 19, 2012
First Posted: July 23, 2012
Last Update Posted: July 23, 2012
Last Verified: July 2012